KRAS and cancer: Survival studies of Ras-driven PDAC are commonly conducted in a p53 mutant background (Ptf1a+/Cre;Kras+/LSL-G12D; Trp53loxP/loxP), where aggressive tumors result in rapid death from cancer (Bardeesy et al. 2006).